Transgender Patients With Hereditary Cancer Risk Variants Benefit From Individualized Approach
Premium
Doctors are using limited guidance on screening and treatment approaches for transgender patients predisposed to cancer while considering patient preferences and treatment goals.
A half-dozen hospital systems plan to implement the tool, which combs through patient medical records to identify those suspected to have high Lp(a).
Merck Talks Up Pipeline Diversification as Keytruda Sales Still Comprise 45 Percent of Q3 Revenues
Premium
The drugmaker emphasized plans to move further away from singular reliance on Keytruda while reporting solid sales growth in the third quarter.
BMS third quarter revenues increased 8 percent to $11.90 billion, with its growth portfolio now making up half of total revenues.
Amgen Sees Strong Growth for Precision Oncology Drugs in Q3
Sales for Lumakras and Blincyto in particular soared during the third quarter as the firm's overall revenues climbed 23 percent year over year.
Lilly to Submit Data on Potential New Kisunla Dosing for Early Symptomatic Alzheimer's
ARIA-E was observed in 14 percent of patients who received a modified dosing regimen, compared to 24 percent of patients who received standard dosing.